Firebrick Pharma (ASX:FRE) received notice of allowance of Nasodine's COVID-19 patent in Mexico, according to a Friday filing with the Australian bourse.
The patent protects the use of Nasodine nasal spray and any other intranasal povidone-iodine preparations as a method of reducing the viral load of SARS-CoV-2 in the nose, the filing stated.
The patent is already granted in the US, Australia, and South Africa, with applications in other countries still pending.
Firebrick Pharma's shares were up nearly 2% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。